论文部分内容阅读
PTCA治疗急性心梗时常规静滴溶栓剂的价值尚不明确,作者前瞻性随机对照研究了血管成形术加用溶栓剂与单用血管成形术的结果,以明确是否血管成形术加溶栓剂能明显保护心室功能。方法患者年龄18～76岁,具有心电图ST段抬高,并且4小时内出现症状,无溶栓治疗反指征,无心源性休克。将他们随机分为安慰剂组和链激酶组,给予静滴10000u肝素,口服325mg阿司匹林,并立即送往导管
The value of conventional intravenous thrombolytic agents in the treatment of acute myocardial infarction with PTCA is not known. Prospective, randomized, controlled, angioplasty and thrombolytic agents alone and angioplasty results were used to determine if angioplasty Suppositories can significantly protect the ventricular function. Methods Patients aged 18 to 76 years, with ST-segment elevation of electrocardiogram, and symptoms within 4 hours, no thrombolysis anti-indications, no cardiogenic shock. They were randomized to placebo and streptokinase, given intravenous drip of 10000u heparin, oral aspirin 325mg, and immediately delivered to the catheter